Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Mitotane in Advanced Adrenocortical Carcinoma
NCT05634577Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in adrenocortical carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate. Started Mar 2023; status: terminated.
02
Drugs
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT05634577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634577.